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a b s t r a c t
Acute gout attacks produce severe joint pain and inﬂammation associated with monosodium urate
(MSU) crystals leading to oxidative stress production. The transient potential receptor ankyrin 1 (TRPA1)
is expressed by a subpopulation of peptidergic nociceptors and, via its activation by endogenous reactive
oxygen species, including hydrogen peroxide (H2O2), contributes to pain and neurogenic inﬂammation.
The aim of this study was to investigate the role of TRPA1 in hyperalgesia and inﬂammation in a model of
acute gout attack in rodents. Inﬂammatory parameters and mechanical hyperalgesia were measured in
male Wistar rats and in wild-type (Trpa1þ /þ) or TRPA1-deﬁcient (Trpa1/) male mice. Animals
received intra-articular (ia, ankle) injection of MSU. The role of TRPA1 was assessed by receptor
antagonism, gene deletion or expression, sensory ﬁber defunctionalization, and calcitonin gene-related
peptide (CGRP) release. We found that nociceptor defunctionalization, TRPA1 antagonist treatment
(via ia or oral administration), and Trpa1 gene ablation abated hyperalgesia and inﬂammatory responses
(edema, H2O2 generation, interleukin-1β release, and neutrophil inﬁltration) induced by ia MSU
injection. In addition, we showed that MSU evoked generation of H2O2 in synovial tissue, which
stimulated TRPA1 producing CGRP release and plasma protein extravasation. The MSU-elicited responses
were also reduced by the H2O2-detoxifying enzyme catalase and the reducing agent dithiothreitol.
TRPA1 activation by MSU challenge-generated H2O2 mediates the entire inﬂammatory response in an
acute gout attack rodent model, thus strengthening the role of the TRPA1 receptor and H2O2 production
as potential targets for treatment of acute gout attacks.
& 2014 Elsevier Inc. All rights reserved.
Gout is the principal cause of inﬂammatory arthritis in men and
postmenopausal women. The identiﬁcation of monosodium urate
(MSU)1 crystals in the joints of gout patients led to the clinical
deﬁnition of gout as an inﬂammatory arthritic disease. However,
MSU crystal deposits in joints and periarticular tissues can also exist
without associated inﬂammatory response [1,2]. Acute attacks of
gout are accompanied by severe joint pain and articular/periarti-
cular inﬂammation and, speciﬁcally, the presence of MSU crystals
in the interior of phagocytic cells [3], which is associated with
neutrophil inﬁltration and production of proinﬂammatory cyto-
kines, mainly represented by interleukin-1β (IL-1β) [1,2].
Regular control using urate-lowering therapies and the reduc-
tion of the incidence of acute gout burdens, by nonsteroidal anti-
inﬂammatory drugs or colchicine (standard therapy to control and
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prevent acute gout attacks), are the most popular therapies for
gout, which, however, may cause signiﬁcant adverse effects, thus
limiting their use. Although new alternatives have been proposed,
such as the modiﬁed uricases (pegloticase) and interleukin-1
inhibitors [2,4,5], gout patients are still undertreated, and novel
strategies for the relief of acute gout attacks with a good efﬁcacy
and safety proﬁle are required.
Previous ﬁndings that endogenous reactive oxygen species are
produced during the process that results in acute gout attack [2,6]
and the observation that the antioxidant vitamin C affords some
beneﬁcial effects on gout [7–9] have suggested the hypothesis that
oxidative stress, by still-unknown mechanisms, contributes to
acute gout attacks. The transient receptor potential ankyrin 1
(TRPA1) is a nonselective cation channel activated by endogenous
reactive oxygen species, including hydrogen peroxide (H2O2) [10].
TRPA1 is coexpressed in sensory neurons along with the hot chili
pepper receptor, TRP vanilloid 1 (TRPV1), and the vasodilator and
proinﬂammatory neuropeptide calcitonin gene-related peptide
(CGRP) [11–13]. Independent preclinical studies using different
rodent models showed that TRPA1 antagonists inhibit nociception
and inﬂammation [11–13].
Previously, we found that H2O2 production and subsequent
TRPA1 activation contribute signiﬁcantly to painful and inﬂamma-
tory responses induced by MSU subcutaneous injection [14].
However, MSU injection into the articular tissue of the ankle
seems to represent a more reliable model of acute gout attack than
the injection into the subcutaneous tissue, and it is interesting to
note that resident cells present in the synovial cavity are con-
siderably different from those in the intraplantar tissue [14–19].
In addition, there are poor data showing the TRPA1 role in
articular models of pain and inﬂammation. Thus, the understand-
ing of TRPA1 participation in the inﬂammatory and painful
processes after ia injection of MSU crystals is critical to guide the
use of TRPA1 antagonists in this pathology. The aim of this study
was to investigate the role of TRPA1 and H2O2 production in the
mechanical hyperalgesia and inﬂammatory responses in an articu-
lar model of acute gout attack in rodents
Materials and methods
Ethical statement
All experiments were carried out according to the current
guidelines for the care of laboratory animals (European Commu-
nities Council (ECC) guidelines for animal care procedures and the
Italian legislation (DL 116/92) application of the ECC directive
86/609/EEC) and ethical guidelines for investigations of experi-
mental pain in conscious animals [17]. All protocols were also
approved by the Ethics Committees of the Federal University
of Santa Maria (Process No. 108/2011(2)) and the University
of Florence (Research Permit 143/2008-B and 204/2012-B). To
describe the behavioral studies, we have followed the ARRIVE
guidelines [18]. Moreover, this study was performed carried out in
accordance with the uniform requirements for manuscripts sub-
mitted to biomedical journals.
Animals
Experiments were performed using adult male Wistar rats
(150–200 g, bred in our vivarium) and littermate wild-type
(Trpa1þ /þ) or TRPA1-deﬁcient (Trpa1 /; B6;129P-Trpa1tm1-
Kykw/J) mice (20–30 g), which were generated by crossing hetero-
zygous animals on a C57BL/6 background (The Jackson Laboratory,
Bar Harbor, ME, USA) [19]. Animals were housed in a controlled-
temperature environment in individually ventilated rat or mouse
cages (5 per cage for rats, 10 per cage for mice with wood shaving
bedding and no environment enrichment) maintained at 2271 1C.
Animals were maintained on a 12-h light/dark cycle (lights on
from 6:00 AM to 6:00 PM) and fed with rodent chow (Puro Lab 22
PB pelleted form, Puro Trato, Rio Grande do Sul, Brazil, for rats or
Global Diet 2018, Harlan, Lombardia, Italy, for mice) and tap water
ad libitum. Before experiments, animals were allowed to acclima-
tize to the experimental room for at least 1 h and to their housing
environment for at least 72 h after arrival.
Drugs
Unless otherwise indicated, all reagents were from Sigma
(St Louis, MO, USA) and were dissolved in the appropriate vehicle
solutions. The TRPA1-selective antagonist HC-030031 was synthe-
sized as previously described [20].
Study design
The primary outcome in the behavioral experiments was
mechanical hyperalgesia, and the secondary outcome was edema
formation after the ia injection of MSU or H2O2. These responses
were evaluated in the same group of animals for all the treat-
ments. For behavioral experiments, we used a group size of six rats
(or six samples) or seven mice for all tests. The group size for each
experiment was determined by sample size estimation [21]
(analysis of variance sample sizes, desired power 0.8, α ¼ 0.05,
standard deviation ¼ 4.5 and difference to detect ¼ 6.5 for rats, or
standard deviation ¼ 0.25 and difference to detect ¼ 0.33 for
mice) for each experiment, based on previous results obtained in
our laboratory, in which we have observed mechanical hyperalge-
sia after MSU ia injection. Each experiment was repeated two or
three times. Allocation concealment was not performed before the
measure of the baseline threshold of animals, in order to yield
groups with similar range basal values in the initial phase of the
experiment (before the ia injection of MSU). Experimenters were
blinded to the genotype and the drug treatment when performing
the tests and to the experimental group when performing analysis.
The inclusion and exclusion criteria for the behavioral test were
the development of mechanical hyperalgesia and edema formation
that were changed by at least 30% compared with the baseline
values. No animal or sample was excluded from the analysis.
Experiments were conducted between 8:00 AM and 5:00 PM.
Procedures for MSU ia injection and behavioral experiments
Intra-articular injection of MSU crystals
An endotoxin-free MSU crystal suspension in phosphate-
buffered saline (PBS) (with a mean length of 1272 μm) [22],
vehicle, or drugs in a volume of 50 or 20 ml (1.25 mg/site) for rats
and mice, respectively, was injected into the medial side of the left
tibiotarsal joint (ankle) under isoﬂurane anesthesia [15,16].
Mechanical hyperalgesia
Mechanical hyperalgesia, observed as an increase in nocicep-
tive response, was assessed according to a previously reported
procedure and expressed as 50% mechanical paw withdrawal
threshold (in g) [23,24].
Edema formation
Edema formation was described as the difference (Δ) between the
basal value and the test value measured using a digital caliper [22].
G. Trevisan et al. / Free Radical Biology and Medicine 72 (2014) 200–209 201
Evaluation of inﬂammatory cell accumulation and measurement
of CGRP and cytokine content
Hematoxylin and eosin (H&E) staining and histological evalua-
tion of emigrated neutrophils was performed after the ia injection
of MSU (1.25 mg/site) in articular tissue [25]. Furthermore, various
inﬂammatory parameters were evaluated after MSU injection in
synovial lavage samples [26]. The total number of cells was
counted using a Neubauer chamber [26]. Myeloperoxidase (MPO)
activity was determined as described previously [27]. Protein
content in the synovial ﬂuid was determined as described else-
where [28]. We also measured the CGRP-like immunoreactivity
(CGRP-LI) in the synovial ﬂuid as previously described using a
commercial ELISA kit (Bertin Pharma, France) [29]. Moreover, the
synovial ﬂuid was also assayed for IL-1β content using an ELISA kit
(PeproTech, Rocky Hill, NJ, USA) [14].
Procedures for drug treatment
Here, we observed the antinociceptive and anti-inﬂammatory
effects of drugs using the time points of 1 and 4 h after MSU
injection. The 1-h time point was chosen because, at that time, we
observed all the nociceptive signs without cellular inﬁltration;
however, at the 4-h time point, we observed the nociceptive and
inﬂammatory signs. The selective and the poorly selective TRPA1
antagonists HC-030031 (300 nmol/site) and camphor (150 nmol/
site), respectively, or a vehicle solution (50 ml/site, 0.1% dimethyl
sulfoxide (DMSO) in PBS) was co-injected ia with MSU (1.25 mg/
site), the TRPA1 agonist allyl isothiocyanate (AITC; 1 nmol/site), or
H2O2 (3 mmol/site), or vehicle. In addition, we tested whether the
systemic administration of HC-030031 (300 mmol/kg, po) or vehicle
(1% DMSO in PBS, 1 ml/kg, po) 1 h before the ia injection of MSU
(1.25 mg/site) or vehicle (PBS, 50 ml) reduced MSU-mediated noci-
ception and edema. In addition, MSU crystals (1.25 mg/site, 20 ml) or
PBS (20 ml/site) was injected ia into Trpa1 / and Trpa1þ /þ mice,
and mechanical hyperalgesia and edema were evaluated as
described above.
To explore the considerable role of TRPA1-positive ﬁbers in
MSU-induced nociception and edema formation, we also employed
an ablation protocol using a perineural injection of capsaicin [22].
Animals were used after 7 days to observe the responses to ia
injection of MSU crystals (1.25 mg/site), AITC (1 nmol/site; a TRPA1
agonist used as a positive control), or vehicle (50 ml/site). In a
different set of experiments, catalase (a H2O2-detoxifying enzyme)
from bovine liver (300 UI/site), dithiothreitol (DTT; 20 nmol/site),
apocynin (a NADPH-oxidase inhibitor, 1 mg/site), a CGRP antagonist
(CGRP 8-37, 1 nmol/site), or vehicle (50 ml/site) was co-injected ia
with MSU (1.25 mg/site), H2O2 (3 mmol/site), or vehicle (50 ml/site).
The treatment time and drug doses were based on published data
as well as on pilot experiments using positive controls (data not
shown). Animals were sacriﬁced with a high dose of intraperitoneal
sodium pentobarbital (200 mg/kg).
Western blot analysis
Western blot analysis was carried out as described previously
[14,22]. Ponceau staining served as a loading control. A speciﬁc
anti-TRPA1 primary antibody (anti-TRPA1 polyclonal antibody;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used. The
results were normalized to the control group densitometry values
and expressed as the relative amount of TRPA1 immunoreactivity.
Real-time PCR
Spinal cord and fresh blood were taken from sacriﬁced mice.
Lymphocytes and granulocytes were separated by density gradient
centrifugation using Ficoll Paque (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden). Total cellular RNA was extracted from spinal
cord by using the TRIZOL method (Invitrogen), cDNA was prepared
from total RNA using the iScript cDNA synthesis kit (Bio-Rad,
Milan, Italy), and the real-time PCR was performed using Sybr
green (SsoAdvanced SYBR Green Supermix, Bio-Rad), to check the
TRPA1 mRNA levels compared to 18S rRNA.
Determination of hydrogen peroxide levels
H2O2 content in synovial tissue was assessed after ia injection
of MSU (1.25 mg/site) or vehicle (50 ml/site) at different time
points (1 and 4 h) using the phenol red–HRPO method [14].
Assessment of synovial production of hydrogen peroxide after MSU
challenge in vitro
Brieﬂy, rat knee synovial membrane was removed and assayed
as described previously [30]. After a stabilization period (2 h),
tissues were incubated with MSU (25 mg/ml) or vehicle (assay
buffer). Then, after various time points (0.25 to 4 h), aliquots
(100 ml) were removed for H2O2 measurement as described above.
We also incubated the synovial membranes with colchicine
(10 mM) or vehicle (assay buffer), and after 1 h, the tissues were
treated with MSU (25 mg/ml) or vehicle [31].
Evaluation of catalase (CAT) activity
To evaluate CAT activity, we used the method described before
[32]. Brieﬂy, 1 or 4 h after vehicle or MSU injection (with or
without catalase co-injection, 300 UI/site), we collected samples of
articular lavage using PBS (pH 7.4, 10 mM); and also periarticular
tissue was collected and homogenized with PBS (pH 7.4, 10 mM).
Both samples were centrifuged at 5000 g, 4 1C, for 10 min. The
synovial ﬂuid pellet was separated and resuspended in PBS, and
synovial ﬂuid and tissue supernatants were also separated for
analysis. The reaction was started by mixing 25-μl samples with
150 μl of PBS containing 0.02 mM H2O2 at 37 1C. The reaction was
monitored every 20 s for 2 min (240 nm). The results were
expressed as millimoles of H2O2 consumed per minute per micro-
liter of sample (synovial ﬂuid supernatant and pellet) or milligram
of protein (tissue supernatant).
Statistical analysis
All results were expressed as the mean 7 SEM. Before
statistical signiﬁcance analysis was performed, data were tested
for normality using the Kolmogorov–Smirnov test and for homo-
geneity using the Bartlett test. Hyperalgesia data were log trans-
formed to meet parametrical assumptions. The difference between
two groups at one time point was analyzed by Student's t test;
differences among three or more groups at one time point were
analyzed by one-way analysis of variance (ANOVA) followed by
Bonferroni's test; differences among three or more groups at
different times were analyzed by two-way ANOVA followed by
Bonferroni's test. Statistical analysis was performed using Graph-
Pad Software 5.0 (GraphPad Software, San Diego, CA, USA).
The percentage inhibition values were reported as the mean 7
SEM obtained in each experiment in relation to the control values.
P values less than 0.05 were considered signiﬁcant. To meet the
ANOVA assumptions, the mechanical hyperalgesia data were log
transformed before statistical analysis.
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Fig. 1. Inﬂammatory responses induced by intra-articular (ia) injection of monosodium urate crystals were mediated by TRPA1 channel activation in rodents. (A) Mechanical
hyperalgesia and (B) edema caused by ia injection of MSU were reduced by co-injection with the selective and the poorly selective TRPA1 antagonists HC-030031 (300 nmol/
site, ia) and camphor (150 nmol/site, ia), respectively. HC-030031 oral pretreatment (300 mmol/kg, 1 h before MSU injection) also reduced the (C) mechanical hyperalgesia
and (D) edema induced by ia MSU injection. TRPA1-deﬁcient mice (Trpa1 /) showed reduced (E) mechanical hyperalgesia and (F) edema formation in response to ia MSU
injection compared with Trpa1þ /þ mice. B represents the baseline threshold of animals. Each column represents the mean 7 SEM of six rats or seven mice. Signiﬁcance
levels: nP o 0.05, nnnP o 0.001 compared with the vehicle (Veh)-treated group (Trpa1þ /þ treated mice in (E) and (F)); #P o 0.05 compared with the MSU-treated group
(Trpa1þ /þ treated mice in (E) and (F)); two-way ANOVA followed by Bonferroni's post hoc test.
Table 1
Controls for the pharmacological treatments.
Treatment 1 h after treatment 4 h after treatment
Mechanical hyperalgesia
(PWT in g)
Δ Paw thickness
(mm)
Mechanical hyperalgesia
(PWT in g)
Δ Paw thickness
(mm)
Vehicle (100 ml/site) 5179 0.270.05 5075 0.270.06
HC-030031 (300 nmol/site) 5279 0.270.05 5674 0.370.07
Camphor (150 nmol/site) 4377 0.270.07 4475 0.370.02
AITC (1 nmol/site) 1074nnn 0.670.07n 972nnn 1.770.2nnn
AITC (1 nmol/site) þ HC-030031 (300 nmol/site) 5175# 0.370.1# 3679# 0.970.3#
AITC (1 nmol/site) þ camphor (150 nmol/site) 4576# 0.370.3# 4677# 0.970.2#
Data are presented as the mean 7 SEM. Mechanical hyperalgesia is expressed as 50% mechanical paw withdrawal threshold (PWT in g). Signiﬁcance was calculated using
two-way ANOVA followed by Bonferroni's post hoc test.
n P o 0.05, compared with vehicle.
nnn P o 0.001, compared with vehicle.
# P o 0.05, compared to AITC-treated group.
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Results
MSU-induced edema and hyperalgesia after ia injection are largely
mediated by TRPA1 receptor activation
Before MSU injection, the animals were healthy and without any
detectable hyperalgesia or edema (data not shown). Local treatment
with the TRPA1-selective antagonist HC-030031 (300 nmol/site, ia) or
with the poorly selective TRPA1 antagonist camphor (150 nmol/site,
ia) was able to decrease MSU-induced hyperalgesia and also edema
1 and 4 h after treatment (Fig. 1A and B). In addition, ia injection of the
selective TRPA1 agonist AITC caused nociceptive and edematogenic
responses, which were markedly reduced by the TRPA1 antagonists
(HC-030031 or camphor, ia) (Table 1). Oral administration of HC-
030031 (300 mmol/kg, po) also largely reduced the development of
MSU-elicited hyperalgesia and edema formation from 1 to 4 h after
treatment (Fig. 1C and D). HC or camphor per se did not produce any
measurable inﬂammatory response compared to vehicle (Fig. 1).
Trpa1þ /þ mice showed mechanical hyperalgesia and edema for-
mation after ia injection of MSU at all evaluated time points. However,
Trpa1 / mice presented a marked reduction in MSU-trigged
responses (Fig. 1E and F). Further, in naïve rats, ablation of TRPA1-
positive nerves by perineural injection of capsaicin reduced TRPA1
channel immunoreactivity in the synovial tissue (64% reduction) 7 days
after treatment (Fig. 2A). In addition, ablation of TRPA1-positive ﬁbers
was associated with diminished MSU- and AITC-induced hyperalgesia
and edema from 1 to 4 h (Fig. 2B and C).
MSU ia injection increases TRPA1 expression in synovial tissue
and CGRP release
MSU increased TRPA1 expression 2.5-fold in synovial tissue 4 h, but
not 1 h, after ia injection of MSU (Fig. 3A). However, we did not
observe any TRPA1 mRNA expression in lymphocytes and granulo-
cytes taken from rodent blood, compared to samples obtained from
mouse spinal cord (Fig. 3B).
TRPA1 neuronal activation was assessed by measuring CGRP-LI
release by MSU, which produced a 1.5-fold increase in synovial lavage
ﬂuid compared to vehicle, and HC-030031 administration reduced
CGRP-LI release (Fig. 3C). The H2O2-detoxifying enzyme catalase
abolished CGRP-LI release after MSU injection, suggesting a role for
endogenous H2O2 in the TRPA1-mediated MSU response (Fig. 3C).
In addition, the co-injection of the CGRP antagonist (CGRP
8-37) was able to decrease the nociception and edema formation
induced by MSU ia injection (Fig. 3D and E).
MSU challenge increased H2O2 production and reduced CAT activity
MSU injection (25 mg/ml) at 1 and 4 h increased synovial tissue
H2O2 levels (Fig. 3F). The MSU challenge also increased synovial
membrane H2O2 production at various time points (0.25 to 4 h). In
addition, pretreatment of the synovial membranes with colchicine
(10 mM for 1 h) reduced the H2O2 production (Fig. 3G).
Moreover, MSU ia injection increased the CAT activity in the
synovial ﬂuid (pellet and supernatant, after 4 h) and also in the
synovial tissue (after 1 and 4 h; Fig. 4A–C). The ia co-injection of
exogenous catalase reduced this effect in all measured samples and
also increased the CAT activity after 1 h in the synovial ﬂuid samples,
compared to vehicle-treated animals (Fig. 4A–C).
The inﬂammatory responses elicited by ia injection of MSU were
possibly mediated by hydrogen peroxide production and subsequent
TRPA1 activation
H2O2 (3 mmol/site, ia) injection induced mechanical hyperalge-
sia and edema. TRPA1 antagonists (HC-030031 and camphor)
reduced the mechanical hyperalgesia and edema formation
induced by ia injection of H2O2 after 1 and 4 h (Fig. 4A and B).
Catalase (300 UI/site) diminished either MSU- or H2O2-induced
hyperalgesic and edematogenic responses at 1 and 4 h (Fig. 4C and
D). The reducing agent DTT (20 nmol/site), which reverses TRPA1
activation by H2O2 in vitro [33], also decreased MSU- or H2O2-
induced hyperalgesia and edema (Fig. 4E and F). Moreover, the
Fig. 2. Ablation of TRPA1-positive ﬁbers largely reduced inﬂammatory responses
elicited by injection of monosodium urate crystals. (A) Western blot (inset)
showing TRPA1 immunoreactivity in synovial tissue samples 7 days after the
injection of capsaicin (CPS; 2%) or vehicle (Veh). Western blot results are expressed
as % of control. The perineural injection of CPS (2%) 7 days before the ia injection of
MSU (1.25 mg/site) crystals, the TRPA1 agonist AITC (1 nmol/site), or vehicle
reduced the (B) mechanical hyperalgesia and (C) edema formation induced by
MSU or AITC ia injection in rats. B represents the baseline threshold of animals.
Each column represents the mean 7 SEM of six rats, except for Western blot, for
which three to four samples were used. Signiﬁcance levels: nP o 0.05, nnnP o 0.001
compared with the Veh-treated group (pretreated with Veh); #P o 0.05 compared
with the MSU- or AITC-treated group (pretreated with Veh); Student's
t test (in A) or two-way ANOVA followed by Bonferroni's post hoc test (in B and C).
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NADPH-oxidase inhibitor apocynin reduced the hyperalgesia and
edema caused by MSU ia injection (Fig. 4G and H).
MSU-induced increases in neutrophil inﬁltration, plasma
extravasation, and IL-1β levels were largely reduced by TRPA1
antagonism or by catalase
We found that MSU (1.25 mg/site, ia) signiﬁcantly increased the
number of emigrated neutrophils in H&E-stained slices of articular
tissue at 4 h, but not 1 h, after injection (Fig. 5A and B). The
inﬂammatory effect induced by MSU was reduced by co-injection
(300 nmol/site, ia) or oral pretreatment with HC-030031
(300 mmol/kg, 1 h before; Fig. 5A and B). Finally, HC-030031 or
catalase injection reduced the number of neutrophils (Fig. 5C), the
MPO activity (Fig. 5D), the plasma extravasation (Fig. 5E), and the
increase in IL-1β content (Fig. 5F) observed in the synovial tissue
4 h after ia MSU challenge. Moreover, CGRP antagonist (CGRP
8-37) and NADPH-oxidase inhibitor (apocynin) injection reduced
the number of neutrophils induced by MSU ia injection (Fig. 5C).
Discussion
Hyperalgesia and edema are major symptoms in patients
affected by acute gout attacks, and the reduction of pain hyper-
sensitivity and inﬂammation is a main therapeutic goal for gout
treatment [34]. The major ﬁnding of this study is that pharmaco-
logical blockade or genetic ablation of the TRPA1 channel mark-
edly decreases the mechanical hyperalgesia and the entire
inﬂammatory repertoire produced by ia injection of MSU, a
predictive rodent model of acute gout attack. Moreover, we
showed that resident cells from the articular space are important
to drive the initial inﬂammatory process, an effect that we did not
observe in our previous study of MSU injection in the intraplantar
tissue (subcutaneous). Thus, our data add signiﬁcant novelty to the
understanding of TRPA1 participation in a model of acute gout in
rats and mice.
A series of studies reported the contribution of TRPA1 to
hyperalgesia and edema in inﬂammatory pain models [11–13].
TRPA1 is co-expressed with TRPV1 in peptidergic sensory neurons
[35]. This implies that the known ability of capsaicin to produce
desensitization of TRPV1-expressing neurons results in profound
desensitization of TRPA1-positive, peptidergic afferents [36].
In addition, the use of capsaicin as a counterirritant to treat gout
pain is probably based on the desensitization properties of the
drug [35]. Here, we showed that capsaicin desensitization pro-
duced antinociceptive and anti-inﬂammatory effects by defunctio-
nalizing TRPA1-expressing neurons. The observation that capsaicin
treatment decreased TRPA1 immunoreactivity in the synovial
tissue may be explained by the ablation of sensory nerve terminals
by the desensitizing action caused by intense TRPV1 stimulation.
Furthermore, we observed that the TRPA1 neuronal activation
by MSU injection increased CGRP release, and this effect was
blocked by TRPA1 antagonism and the use of the H2O2-detoxifying
enzyme catalase. In accordance with these data the CGRP antago-
nist (CGRP 8-37) reduced MSU-induced hyperalgesia and edema,
showing that TRPA1 activation produced CGRP release driving
inﬂammation and pain. However, MSU crystals or uric acid do not
directly stimulate TRPA1, whereas H2O2 promotes TRPA1 activa-
tion [10,14]. Injection of MSU (ia) increased the H2O2 levels in
synovial membranes in vitro, an effect that was reduced by
colchicine, indicating a role of MSU phagocytosis in this process.
Fig. 3. Monosodium urate crystal-elicited nociceptive and edematogenic responses were accompanied by an increase in TRPA1 expression, release of CGRP, and H2O2
production and a reduction in catalase activity by the synovial tissue. (A) Western blot (inset) showing TRPA1 immunoreactivity in synovial tissue at 1 and 4 h after the ia
injection of MSU (1.25 mg/site) or vehicle (Veh). Western blot results are expressed % of control. (B) TRPA1 mRNA levels normalized to 18S in spinal cord, lymphocytes, and
granulocytes. The expression in lymphocytes and granulocytes is almost zero compared to the TRPA1 expression in mouse spinal cord. (C) Calcitonin gene-related peptide-
like immunoreactivity (CGRP-LI) was increased 15 min after MSU (1.25 mg/site) ia injection, an effect reduced by co-injection with HC (300 nmol/site) or CAT (300 UI/site) or
by oral pretreatment with HC (300 mmol/kg, 1 h). The CGRP-LI assay was performed in the synovial lavage samples obtained from pretreated rats. The CGRP antagonist (CGRP
8-37, 1 nmol/site, ia), when co-injected with MSU (1.25 mg/site, ia), decreased the (D) mechanical hyperalgesia and (F) edema formation induced by MSU. (E) The ia injection
of MSU (1.25 mg/site) crystals increased H2O2 content in synovial tissue 1 or 4 h after administration compared with samples from vehicle (50 ml/site)-injected animals.
(G) Incubation with MSU (25 mg/ml) of rat synovial membranes in vitro enhances the production of H2O2 at various time points (0.25 to 4 h), and pretreatment of the
membranes with colchicine (10 mM for 1 h) reduced the H2O2 production by rat synovial membranes challenged with MSU (25 mg/ml). B represents the basal level of H2O2
production. The data are expressed as the mean 7 SEM of six rats or six samples, except for Western blot, for which three to four samples were used. Signiﬁcance levels:
nP o 0.05, nnP o 0.01, nnnP o 0.001 compared with the Veh-treated group; or #P o 0.05, ##P o 0.05 compared with the MSU-treated group; Student's t test (in A and B)
and one-way ANOVA (in C and D) or two-way ANOVA followed by Bonferroni's post hoc test (in E, F, and G).
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Previous ﬁndings show that MSU challenge generated oxidative
stress from resident cells and neutrophils, and both responses
were reduced by colchicine [31,37,38]. Thus, by analogy, we
propose that resident synovial cells, which have the potential to
phagocytize MSU crystals, generate H2O2 when challenged with
MSU. In the normal synovial tissue, type A synoviocytes are known
to exert a macrophage-like behavior, with the associated phago-
cytic activity [39–41]. Previously, it has been described that
injection of MSU crystals into the synovial space in dogs produced
an inﬂammatory response (marked inﬁltration of neutrophils) that
was initiated by premature MSU crystal phagocytosis by resident
cells (synovial lining cells) in the synovial space [42].
Consistent with these ﬁndings, ia injection of H2O2 evoked
nociception and inﬂammation in a TRPA1-dependent manner.
In addition, catalase or the reducing agent DTT decreased
these effects. Moreover, we observed that catalase activity was
decreased after MSU ia injection in the synovial ﬂuid (supernatant,
which represents the extracellular enzyme, and pellet, which
represents intracellular enzyme, after 4 h) and also in the synovial
tissue (1 and 4 h after MSU injection). In addition, the inhibition of
NADPH oxidase by apocynin was able to reduce MSU-induced
hyperalgesia, edema, and inﬂammatory cell inﬁltration. Then, the
increase in NADPH oxidase and the decrease in catalase activities
after MSU ia injection may account for the observed H2O2
production, which could in turn activate the TRPA1 receptor
causing hyperalgesia and inﬂammation. In this context, it should
be emphasized that gout patients show levels of reactive oxygen
species higher than those present in normal subjects [3,6].
MSU-mediated inﬂammation has been linked to IL-1β produc-
tion, which follows the activation of inﬁltrating cells [43–45].
Indeed, neutralization of IL-1β has been explored as a new
strategy for the relief of gout pain [46,47]. However, the present
data indicate that TRPA1 activation, presumably by H2O2, is
upstream of neutrophil inﬁltration and increased IL-1β produc-
tion. In fact, early blockade of TRPA1 receptor or of H2O2 produc-
tion by catalase reduced the MSU-evoked increase in IL-1β, MPO
activity, or neutrophil accumulation in the synovial space. Also,
CGRP antagonism and NADPH-oxidase blockage reduced the
neutrophil accumulation in the synovial ﬂuid.
The increase in TRPA1 expression after MSU injection was
delayed and this fact is consistent with the time lag usually
required either for new protein generation or for transport to
the nerve terminals. The temporal association between the
increase in TRPA1 expression and the continuation of the hyper-
sensitivity and inﬂammatory condition suggests that maintenance
rather than onset of these phenomena is dependent on augmented
channel expression. It is possible, as observed by others [48],
that inﬂammatory mediators, including IL-1β, promote TRPA1
Fig. 4. Monosodium urate crystal-induced nociception and edema were mediated via activation of TRPA1 receptors by hydrogen peroxide. The ia injection of MSU altered the
catalase (CAT) activity observed in the synovial ﬂuid (A) pellet and (B) supernatant samples or in the (C) synovial tissue, and the co-injection of CAT (300 UI/site, ia) with
MSU (1.25 mg/site, ia) prevented this effect. The selective and nonselective TRPA1 antagonists HC-030031 (300 nmol/site, ia) and camphor (150 nmol/site, ia), respectively,
when co-injected with H2O2 (3 mmol/site, ia) decreased the (D) mechanical hyperalgesia and (E) edema formation induced by this TRPA1 agonist. The co-injection of CAT
(300 UI/site, ia) with H2O2 (3 mmol/site, ia) or MSU (1.25 mg/site, ia) crystals reduced the (F) mechanical hyperalgesia and (G) edema formation. The reducing agent DTT
(20 nmol/site, ia) was co-injected with MSU (1.25 mg/site, ia) or H2O2 (3 mmol/site, ia), and it reduced the (H) mechanical hyperalgesia and (I) edema induced by ia injection
of MSU or H2O2. The NADPH-oxidase inhibitor apocynin (Apo; 1 mg/site, ia) reduced the (J) hyperalgesia and (K) edema caused by MSU (1.25 mg/site, ia) injection. B
represents the baseline threshold of animals. Each column represents the mean 7 SEM of six rats. Signiﬁcance levels: nP o 0.05, nnnP o 0.001 compared with vehicle (Veh)-
treated group; or #P o 0.05, ##P o 0.05 in comparison to MSU- or H2O2-treated group; one-way (A–C) or two-way (in D–K) ANOVA followed by Bonferroni's post hoc test.
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expression and contribute, by this and other mechanisms, to
increased ﬁring of nociceptive neurons and nociception [11,49].
As presented in Fig. 3, TRPA1 is not expressed in leukocytes,
indicating that TRPA1 increased expression is not caused by TRPA1
expressed in inﬁltrating cells. Thus, we speculate that the increase
in TRPA1 expression is mediated by local protein synthesis
by a resident cell, especially sensory neurons because they
may quickly synthesize protein in their axons [50] and their
Fig. 5. Monosodium urate crystal-induced inﬂammatory response is largely reduced by TRPA1 antagonism and blockade of H2O2 production. (A) Representative images and
(B) pooled data showing the accumulation of emigrated neutrophils induced by the ia injection of MSU (1.25 mg/site) in rats at different time points (1 and 4 h), evaluated by
H&E staining and histological analysis. The ia co-injection of MSU with the TRPA1 antagonist HC-030031 (HC, 300 nmol/site) and oral (po) pretreatment with HC (300 mg/kg,
1 h) signiﬁcantly reduced the emigration of neutrophils 4 h post-MSU injection. HPF, high power ﬁeld; original magniﬁcation 200; scale bar, 100 mm). The ia co-injection of
MSU (1.25 mg/site) with HC (300 nmol/site) or catalase (CAT; 300 UI/site) and oral pretreatment with HC-030031 (300 mg/kg, po, 1 h) decreased the (C) neutrophil
inﬁltration, (D) MPO activity, (E) plasma extravasation, and (F) IL-1β levels observed 4 h after ia MSU injection. In addition, (C) the ia co-injection of MSU (1.25 mg/site) with
the CGRP receptor antagonist (Ant-CGRP; CGRP 8-37, 1 nmol/site) or apocynin (Apo; 1 mg/site) decreased the neutrophil inﬁltration. All the measurements were performed
using synovial lavage samples obtained from pretreated rats. Each column represents the mean 7 SEM of six samples. Signiﬁcance levels: nnP o 0.01, nnnP o 0.001
compared with the vehicle (Veh)-treated group; or #P o 0.05, ##P o 0.01, ###P o 0.001 compared with the MSU-injected group; one-way ANOVA followed by Bonferroni's
post hoc test.
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defunctionalization is largely able to reduce either TRPA1 expres-
sion or MSU-triggered inﬂammation. However, we cannot exclude
that the increased expression of TRPA1 could also occur in other
cell types present in the synovial cavity, such as synoviocytes [11].
Additional studies must be carried out to clarify the types of cells
in which the TRPA1 receptor protein has an increased expression
after MSU ia injection.
In conclusion, as previously observed in subcutaneous tissue,
our present data support the notion that early TRPA1 activation by
endogenous reactive oxygen species in the synovial tissue
mediated nociceptive and inﬂammatory responses induced by
MSU ia injection. These ﬁndings point to TRPA1 antagonism and
the detoxifying of H2O2 production by catalase as a possible novel
therapeutic option for gout treatment.
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